Afghanistan’s pharma factories produce 900 medicines, eye expansion
Union of Pharmaceutical Factories urges greater coordination as sector grows, warns challenges could threaten progress
KABUL, Afghanistan (MNTV) — Afghanistan’s pharmaceutical sector is witnessing steady growth, with local factories producing nearly 900 different types of medicines, officials said.
According to a report by Ariana News, members of the Union of Pharmaceutical Factories emphasized that around 100 types of medicines have already reached self-sufficiency levels, reducing reliance on imports.
Union leaders are calling on ministries, including the Ministry of Public Health, to strengthen coordination with private sector stakeholders when drafting policies and investment frameworks. They argue that closer collaboration is vital to sustain and expand the industry’s progress.
“Currently, production of up to 900 types of medicine is underway in various forms. Afghanistan’s domestic pharmaceutical output could meet market demand with high-quality production of over 100 more medicines — if drug imports are restricted,” said Ahmad Saeed Shams, head of the union.
Government officials have also highlighted the sector’s strategic importance. Abdul Latif Nazari, Deputy Minister of Economy, stated that the Taliban-led Afghanistan government is prioritizing support for domestic industries as part of its broader economic strategy.
“The Islamic Emirate’s strategy in all sectors, including pharmaceuticals, is import substitution. We aim to increase exports in every area, and supporting domestic production is at the top of our agenda,” Nazari said.
Economic analysts agree that government intervention is critical. They have urged authorities to offer greater incentives and support mechanisms to encourage investment in the pharmaceutical industry, warning that inadequate assistance could slow growth.
Despite the progress, challenges persist. The Union of Pharmaceutical Factories warned that without stronger government backing, several manufacturing plants could face closure, threatening the country’s path toward pharmaceutical self-reliance.